Medicine and Dentistry
Neoplasm
100%
Acute Myeloid Leukemia
74%
Diseases
51%
Diffuse Large B-Cell Lymphoma
42%
Myelodysplastic Syndrome
41%
Overall Survival
39%
B Cell
33%
Malignant Neoplasm
33%
B-Cell Chronic Lymphocytic Leukemia
28%
T Cell
25%
Acute Lymphoblastic Leukemia
25%
Diagnosis
24%
Anaplastic Large Cell Lymphoma
22%
Mantle Cell Lymphoma
21%
Leukemia
21%
Morphology
20%
B-Cell Lymphoma
20%
Next Generation Sequencing
17%
Minimal Residual Disease
17%
Cancer
16%
Rituximab
16%
Progression Free Survival
16%
Chronic Myelogenous Leukemia
16%
Flow Cytometry
15%
Non-Hodgkin Lymphoma
15%
Biological Marker
14%
Multiple Myeloma
14%
Immunohistochemistry
14%
Karyotype
13%
Programmed Cell Death
13%
Follicular Lymphoma
12%
Fluorescence in Situ Hybridization
12%
Epstein Barr Virus
12%
Myeloproliferative Neoplasm
12%
Clinical Trial
12%
Radiation Therapy
12%
Immunophenotyping
11%
Breast Cancer
11%
Targeted Therapy
10%
Gene Mutation
10%
T-Cell Lymphoma
10%
Chronic Myelomonocytic Leukemia
10%
Large-Cell Lymphoma
10%
Classical Hodgkin Lymphoma
10%
Prognostic Factor
9%
Breast Implant
9%
Protein P53
9%
Circulating Tumor Cell
9%
Venetoclax
9%
Hematologic Malignancy
9%
Hodgkin's Lymphoma
9%
Lymph Node
9%
Lymphocyte
8%
Biopsy Technique
8%
Philadelphia 1 Chromosome
8%
Acute Leukemia
8%
Cyclophosphamide
8%
Tyrosine-Kinase Inhibitor
8%
MALT Lymphoma
8%
Differential Diagnosis
8%
Tumor Cell
8%
Doxorubicin
8%
Leukemia Cell
7%
Vincristine
7%
Lymphoma Cell
7%
Germinal Center
7%
Hypomethylating Agent
7%
Multivariate Analysis
7%
Survival Rate
6%
Metastatic Carcinoma
6%
Lymphoproliferative Disease
6%
Anaplastic Lymphoma Kinase
6%
Inflammatory Breast Cancer
6%
Immunoglobulin Producing Cell
6%
Arm
6%
Precursor
6%
Lymphoid Leukemia
6%
Risk Stratification
6%
Lymphocytic Lymphoma
6%
Cell Signaling Pathway
6%
Metastatic Breast Cancer
6%
Ibrutinib
6%
Allogeneic Stem Cell Transplantation
6%
Hazard Ratio
5%
Cancer Cell
5%
Myelofibrosis
5%
Imatinib
5%
Acute Myelogenous Leukemia
5%
Janus Kinase
5%
Disease Exacerbation
5%
Hematopoietic Cell
5%
Waldenström's Macroglobulinemia
5%
Myeloma
5%
Stem Cell Transplant
5%
NPM1
5%
Peripheral T-Cell Lymphoma
5%
Myeloid Sarcoma
5%
Chromosome Aberration
5%
CD20
5%
microRNA
5%
Keyphrases
Acute Myeloid Leukemia
66%
Diffuse Large B-cell Lymphoma (DLBCL)
33%
Overall Survival
31%
Chronic Myeloid Leukemia
28%
Myelodysplastic Syndrome
27%
Chronic Lymphocytic Leukemia
25%
Tumor
24%
B-cell Lymphoma 2 (Bcl-2)
23%
Mantle Cell Lymphoma
23%
Bone Marrow
19%
Lymphoma
19%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
17%
Anaplastic Large Cell Lymphoma
16%
Leukemia
15%
Acute Lymphoblastic Leukemia
14%
Complete Remission
14%
Neoplasms
13%
Rituximab
13%
T Cells
13%
Newly Diagnosed
13%
Progression-free Survival
13%
Poor Prognosis
12%
Lymphoma Cells
12%
Apoptosis
12%
Tumor Protein p53 (TP53)
12%
Follicular Lymphoma
12%
Chemotherapy
12%
Myeloid Neoplasms
12%
Venetoclax
12%
Minimal Residual Disease
11%
Overexpression
11%
Lymphoma Patients
10%
Clinical Outcomes
10%
Immunophenotypic Profile
10%
Leukemia Patients
10%
Immunohistochemistry
10%
Next-generation Sequencing
10%
B Cells
9%
Cyclophosphamide
9%
Fluorescence in Situ Hybridization
9%
Clinical Significance
8%
Multiple Myeloma
8%
Non-Hodgkin Lymphoma
8%
MD Anderson Cancer Center
8%
Flow Cytometry
8%
TP53 mutation
8%
Myeloproliferative Neoplasms
8%
Inflammatory Breast Cancer
8%
Phase II Study
8%
B-cell Lymphoma
8%
Relapsed or Refractory
8%
Immunophenotyping
7%
Hypomethylating Agents
7%
Hematological Malignancies
7%
Epstein-Barr Virus
7%
Nucleophosmin 1 (NPM1)
7%
Targeted Therapy
7%
Median Overall Survival
7%
Tyrosine Kinase Inhibitor
7%
Peripheral Blood
7%
High Risk
7%
Circulating Tumor Cells
6%
Acute Leukemia
6%
Anaplastic Lymphoma Kinase
6%
Doxorubicin
6%
Multivariate Analysis
6%
Confidence Interval
6%
Complex Karyotype
6%
Induced Apoptosis
6%
Complete Response
6%
Hodgkin Lymphoma
6%
Lymph Node
6%
Cytogenetic Abnormalities
6%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
6%
Prognostic Significance
6%
FMS-like Tyrosine Kinase 3 (FLT3)
6%
MYC Rearrangement
6%
Remission
6%
Prognostic Impact
6%
Programmed Death-ligand 1 (PD-L1)
6%
Radiation Therapy
6%
Metastatic Breast Cancer
6%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
6%
Oncogene
6%
Cyclin D1 (CCND1)
5%
Differential Diagnosis
5%
Quantitative PCR
5%
Phase II Trial
5%
Hazard Ratio
5%
Prognostic Factors
5%
Intensive Chemotherapy
5%
Large B-cell Lymphoma
5%
Tumor Cells
5%
Disease Progression
5%
T-cell Lymphoma
5%
World Health Organization Classification
5%
Risk Stratification
5%
Stem Cell Transplantation
5%
Poor Outcome
5%
Clinicopathologic Study
5%
Biochemistry, Genetics and Molecular Biology
Myeloid
62%
B Cell
39%
Cytogenetics
30%
Overall Survival
30%
Programmed Cell Death
20%
Genomics
19%
Next Generation Sequencing
17%
T Cell
17%
P53
16%
Cancer Cell
15%
Fluorescence in Situ Hybridization
13%
Genetics
13%
Karyotype
12%
Gene Mutation
10%
Tyrosine Kinase Inhibitor
8%
Philadelphia Chromosome
8%
MicroRNA
8%
Kinase
8%
Phosphotransferase
8%
Gene Expression
7%
Progression Free Survival
7%
Bcl-2
7%
Carcinogenesis
7%
Anaplastic Lymphoma Kinase
7%
Flow Cytometry
7%
Morphology
7%
Oncogene
7%
Wild Type
7%
Clinical Trial
7%
Immunophenotyping
6%
KRAS
6%
STAT3
6%
Single-Nucleotide Polymorphism
6%
Epidermal Growth Factor Receptor
6%
Multivariate Analysis
6%
Hematopoietic Cell
6%
NPM1
6%
Imatinib
5%
Chromosomal Abnormalities
5%
Tumor Suppressor Protein
5%
Cell Death
5%
Germ Cell
5%
Germline
5%
Precursor
5%
CD34
5%
Messenger RNA
5%
Intravenous Immunoglobulin
5%
Stem Cell
5%